Please login to the form below

Not currently logged in

Viking Therapeutics

This page shows the latest Viking Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Gilead lead NASH drug flunks phase 3 test

Gilead lead NASH drug flunks phase 3 test

Nevertheless, William Blair thinks the setback could prompt Gilead to seek out other licensing candidates to expand it liver disease pipeline, and they think one possible candidate could be Viking

Latest news

  • Roche enters NASH race with deal to buy Jecure Roche enters NASH race with deal to buy Jecure

    cutting a deal to acquire US start-up Jecure Therapeutics. ... Other competition is coming from pharma heavyweights Novartis and Pfizer, which recently joined forces to test three drugs in combination, and other clinical-stage player such as Allergan,

  • Viking throws down gauntlet in NASH battle Viking throws down gauntlet in NASH battle

    Impressive data in a phase 2 trial caused shares in Viking Therapeutics to almost double yesterday as investors got excited about another candidate for non-alcoholic steatohepatitis (NASH). ... Viking’s VK2809 – a thyroid hormone receptor beta

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Pharma deals during May 2014 Pharma deals during May 2014

    The acquisition for up to $658m (a 59 per cent premium on the pre-bid share price) of the US company, Chelsea Therapeutics, achieves both those goals. ... As a footnote, Ligand this month licensed to what appears to be a new company called Viking

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs


Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...